enristomig

{
  "id": "MLC-T-ONC-013362",
  "term": "enristomig",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant, humanized, bispecific antibody targeting both the human programmed death-ligand 1 (PD-L1) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), with potential checkpoint inhibitory, immunostimulating and antineoplastic activities. Upon administration, enristomig simultaneously targets and binds to 4-1BB, which is expressed on a variety of leukocyte subsets including activated T lymphocytes, and PD-L1 expressed on tumor cells. Through 4-1BB binding, enristomig acts as a conditional 4-1BB agonist, resulting in T-cell co-stimulation and enhanced anti-tumor activity. At the same time, Ienristomig prevents PD-L1 from binding to and activating its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell inhibition, activates antigen-specific T lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which may lead to a reduction in tumor growth. PD-L1 binding to PD-1 on activated T cells inhibits the expansion and survival of CD8-positive T cells, suppresses the immune system and results in immune evasion. 4-1BB, a surface glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.",
  "synonyms": [
    "PDL1 x 41BB bispecific antibody INBRX-105",
    "PDL1 x CD137 bispecific antibody INBRX-105",
    "anti-PD-L1/CD137 bispecific antibody INBRX-105",
    "Anti-PD-L1/4-1BB bispecific antibody INBRX-105",
    "PDL1 x 4-1BB bispecific antibody INBRX-105"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/enristomig/"
}